Antony CPA - Forte Biosciences Chief Officer
| FBRX Stock | USD 15.96 1.31 8.94% |
Insider
Antony CPA is Chief Officer of Forte Biosciences
| Age | 58 |
| Address | 3060 Pegasus Park Drive, Dallas, TX, United States, 75247 |
| Phone | 310 618 6994 |
| Web | https://www.fortebiorx.com |
Forte Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.8125) % which means that it has lost $0.8125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7091) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2025. Return On Capital Employed is likely to drop to -0.87 in 2025. At this time, Forte Biosciences' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 831.9 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 558.3 K in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eugene Jiang | ABVC Biopharma | 39 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Igor MD | Celcuity LLC | N/A | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Ellen MBA | Werewolf Therapeutics | 49 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Behrad Derakhshan | Edgewise Therapeutics | 45 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Lance Laing | Celcuity LLC | 63 | |
| CPA MS | Erasca Inc | 55 | |
| Eric Lindquist | Celcuity LLC | N/A | |
| Daniel Hicklin | Werewolf Therapeutics | 61 | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
| Brian MD | Rezolute | 50 | |
| ChiHsin King | ABVC Biopharma | 76 | |
| MD MBA | Rezolute | N/A | |
| Brian Sullivan | Celcuity LLC | 63 | |
Management Performance
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.81 |
Forte Biosciences Leadership Team
Elected by the shareholders, the Forte Biosciences' board of directors comprises two types of representatives: Forte Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Forte. The board's role is to monitor Forte Biosciences' management team and ensure that shareholders' interests are well served. Forte Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Forte Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antony CPA, Chief Officer | ||
| Steven Ruhl, Chief Officer | ||
| Paul Wagner, President CEO | ||
| Hubert MD, President Officer | ||
| Christopher Roenfeldt, Chief Officer | ||
| Barbara MD, Chief Director |
Forte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Forte Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.81 | ||||
| Current Valuation | 85.67 M | ||||
| Shares Outstanding | 6.39 M | ||||
| Shares Owned By Insiders | 10.94 % | ||||
| Shares Owned By Institutions | 54.05 % | ||||
| Number Of Shares Shorted | 241.29 K | ||||
| Price To Book | 10.89 X | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (31.48 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.